EUVIMEDEUVIMED entdecken
Crossref

A Preclinical Study of [ 64 Cu]Cu-NOTA-KN035 for Molecular Imaging of PD-L1 in Tumors

Yu Xu, Yuqi Hua iD, Xuwei Liu, Qiaoling Shen, Qi Meng, Xiaoman Shao, Jixiang Sheng, Haitian Fu, Chunjing Yu iD

Molecular Pharmaceutics · 02.03.2026 · 23 (3) · 2151-2164

DOI: 10.1021/acs.molpharmaceut.5c01942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 19.02.2026. Verfasst von Yu Xu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi 214125, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Copper Radioisotopes, Molecular Imaging, Radiopharmaceuticals. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 83 Literaturangaben. Gefördert von: Wuxi Health Select Committee, NHC Key Laboratory of Nuclear Technology Medical Transformation, University of Electronic Science and Technology of China, Wuxi Medicine School, Jiangnan University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The programmed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) axis plays a central role in tumor immune regulation, with PD-L1 expression serving as a critical biomarker for patient stratification and response prediction. Accurate, noninvasive assessment of PD-L1 expression is, therefore, essential for guiding clinical decision-making. KN035 is an ∼79.6 kDa fusion protein comprising a humanized single-domain antibody linked to an Fc fragment, offering a smaller molecular size than conventional monoclonal antibodies. In this study, KN035 was conjugated with p-SCN-Bn-NOTA and radiolabeled with 64 Cu to generate [ 64 Cu]Cu-NOTA-KN035 for PET imaging of PD-L1. The tracer showed high radiochemical purity (>95%) and strong binding specificity in vitro . In vivo PET imaging and biodistribution studies were performed in H1975 (high PD-L1 expression) and A549 (low PD-L1 expression) nonsmall cell lung cancer (NSCLC) xenograft models. Clear tumor visualization was achieved at 4 h postinjection (5.62 ± 0.55%ID/g in H1975; 4.16 ± 0.18%ID/g in A549), with peak uptake at 48 h (12.32 ± 0.66 and 5.72 ± 0.21%ID/g, respectively). Tumor uptake decreased significantly after blocking with excess KN035, confirming the specificity. These results demonstrate the high PD-L1-targeting specificity of [ 64 Cu]Cu-NOTA-KN035, suggesting its great potential as a noninvasive diagnostic tool for immunotherapy-based treatments in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenCopper RadioisotopesMolecular ImagingRadiopharmaceuticalsLung NeoplasmsAnimalsHumansMiceTissue DistributionPositron-Emission TomographyCell Line, TumorFemaleHeterocyclic Compounds, 1-RingXenograft Model Antitumor AssaysMice, Nude

Stichwörter der Autor:innen

64CuPD-L1immuno-PET imagingnonsmall cell lung cancerssingle-domain antibody

Substanzen

B7-H1 AntigenCopper RadioisotopesCD274 protein, humanCopper-64Radiopharmaceuticals1,4,7-triazacyclononane-N,N',N''-triacetic acidHeterocyclic Compounds, 1-Ring

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Affiliated Hospital of Jiangnan University, Wuxi 214125, China.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China.

ORCID-Profile: Yuqi Hua, Chunjing Yu

Förderung

  • Wuxi Health Select Committee
  • NHC Key Laboratory of Nuclear Technology Medical Transformation, University of Electronic Science and Technology of China
  • Wuxi Medicine School, Jiangnan University
  • Wuxi Taihu Lake Talent Plan
  • Wuxi Health Commission

Zitieren

APA

Xu, Y., Hua, Y., Liu, X., Shen, Q., Meng, Q., Shao, X., Sheng, J., Fu, H., & Yu, C. (2026). A Preclinical Study of [ 64 Cu]Cu-NOTA-KN035 for Molecular Imaging of PD-L1 in Tumors. Molecular Pharmaceutics, 23(3), 2151-2164. https://doi.org/10.1021/acs.molpharmaceut.5c01942

Vancouver

Xu Y, Hua Y, Liu X, Shen Q, Meng Q, Shao X, et al. A Preclinical Study of [ 64 Cu]Cu-NOTA-KN035 for Molecular Imaging of PD-L1 in Tumors. Molecular Pharmaceutics. 2026;23(3):2151-2164. doi:10.1021/acs.molpharmaceut.5c01942

BibTeX
@article{Xu2026,
  author = {Xu, Yu and Hua, Yuqi and Liu, Xuwei and Shen, Qiaoling and Meng, Qi and Shao, Xiaoman and Sheng, Jixiang and Fu, Haitian and Yu, Chunjing},
  title = {A Preclinical Study of [ 64 Cu]Cu-NOTA-KN035 for Molecular Imaging of PD-L1 in Tumors},
  journal = {Molecular Pharmaceutics},
  year = {2026},
  volume = {23},
  number = {3},
  pages = {2151--2164},
  doi = {10.1021/acs.molpharmaceut.5c01942}
}
Kostenlos starten →